News
Hims & Hers Jumps 18.2% on Incredible 111% Revenue Growth
Hims & Hers (NYSE: HIMS) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth of 111% and an increase in 2025 guidance. The results were phenomenal and a short squeeze likely helped, which Travis Hoium discusses in this video.
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...
Hims & Hers reports 111% YoY sales growth & 70%+ gross margin. Discover their growth potential, risks, & why it's a Buy ...
Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...
24/7 Wall St. on MSN1d
Hims & Hers (HIMS) Blows Out Earnings ExpectationsHims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.
The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback